Immune Repertoire Sequencing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The immune repertoire sequencing market was valued at USD 327.76 million in 2025 and is estimated to reach USD 358.41 million in 2026. This report is segmented by Product (Instruments, Services, and More), Technology (Sequencing Technologies, and More), Receptor Type (T-Cell Receptor Sequencing, and More), Application (Oncology & Cancer Immunotherapy, and More), End-User (Pharmaceutical and Biotechnology Companies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Immune Repertoire Sequencing Market Trends and Insights

Expansion of Precision Immuno-Oncology and Cell Therapy Biomarker Programs

Immune repertoire data is becoming a defined biomarker endpoint in later-stage immuno-oncology trials rather than remaining a purely exploratory research tool. A 2025 study found that baseline T-cell receptor clonality had value as a response biomarker in non-small cell lung cancer treated with immunochemotherapy. An AACR 2026 presentation described a 96-well workflow for scalable T-cell receptor chain pairing and immunophenotyping from cancer-associated T cells. For the immune repertoire sequencing market, this shifts purchasing toward validated assays and specialized service providers because sponsors need reproducible clinical-grade data across studies, sites, and patient populations. Adaptive Biotechnologies signed 2 nonexclusive immune receptor data licensing agreements with Pfizer in 2025, showing that curated receptor data can be used beyond one testing project. The immune repertoire sequencing market therefore benefits when biomarker strategy, data licensing, and treatment development progress together.

Growing Use of Repertoire Data in Vaccine, Autoimmune, and Infectious Disease Studies

Within the immune repertoire sequencing market, vaccine programs can create recurring test demand because immune responses are measured at several development, safety, and follow-up points. A 2026 Nature Immunology study reported that B-cell receptor sequencing detected changes in IgG clonotype diversity and intraclonal expansion after quadrivalent mRNA influenza vaccination that conventional titer testing did not capture. The CORSA study used T-cell receptor sequencing to identify clonotype-level differences between lymphoma patients and healthy controls following SARS-CoV-2 mRNA vaccination. In Crohn's disease, high-throughput B-cell profiling identified isotype switching patterns in inflamed colon tissue. Research in multiple sclerosis also linked immunoglobulin signatures to disease patterns and treatment responses. These uses give the immune repertoire sequencing market demand sources that are not limited to oncology.

High Capital Intensity, Specialized Bioinformatics Requirements, and Bulk Assay Limits

High equipment costs and scarce data science expertise keep advanced immune profiling concentrated in well-funded institutions. Laboratories must obtain sequencing instruments and consumables while also maintaining expertise in V(D)J alignment, clonotype calling, and statistical analysis. A 2025 review of clinical AIRR-seq deployment identified underrepresented germline and HLA reference databases as a source of potential misassignment errors in non-European populations. High-throughput bulk assays can also lose chain pairing and tissue context, which limits their use where full biological resolution is required. Centralized certified laboratories can address some capability gaps, but they do not remove the costs of sample transfer, data linkage, specialist interpretation, and compliance arrangements needed when patient information crosses institutional or national boundaries. These constraints slow the immune repertoire sequencing market in emerging research settings and favor providers with integrated workflows.

Other drivers and restraints analyzed in the detailed report include:

• Rising Demand for Longitudinal Monitoring in Transplantation and MRD
• Scale-Up of Paired-Chain, Full-Length, and AI-Assisted Receptor Discovery Workflows
• Limited Clinical Validation, Reimbursement, and Data Governance Pathways

Segment Analysis

Assay kits and reagents held 57.62% of the immune repertoire sequencing market share in 2025. Each sequencing run uses library preparation reagents, target enrichment panels, and sequencing chemistry, which makes consumable demand repeatable regardless of instrument age. Capture-based enrichment kits can increase per-run reagent spending because they require more complex panels and validation than older amplicon methods. Instruments and software held lower revenue positions, but instrument placements create future consumable demand. Software licenses are increasingly bundled into platform agreements, strengthening customer retention. These conditions keep kits and reagents as the revenue foundation of the immune repertoire sequencing industry, and they make the immune repertoire sequencing market less dependent on one-time capital equipment purchases.

Services is forecast to expand at a 9.81% CAGR through 2031, the highest rate in the product segmentation. Pharmaceutical sponsors often need validated AIRR-seq results but do not maintain internal clinical-grade processing capability. Specialized providers are also adding clinical support and patient stratification services that give oncologists interpretable immune repertoire findings. This integration of testing and interpretation was limited in AIRR-seq services before 2024, when suppliers more commonly delivered sequence outputs without the same degree of workflow support for clinical users. Parse Biosciences, now a QIAGEN company, introduced next-generation Evercode TCR and BCR kits and an integrated immune repertoire and transcriptome workflow on its Trailmaker platform in early 2026. Such integrated offerings may raise the value of kit bundles while increasing pressure on standalone software vendors, as customers favor fewer handoffs between library preparation, sequencing, and downstream interpretation.

Sequencing technologies accounted for 53.25% of revenue in 2025. Illumina's short-read platforms have a broad installed base across academic and clinical facilities, including NextSeq and NovaSeq systems. In July 2026, Illumina announced a NovaSeq X roadmap addition with a 1.5B 600-cycle kit designed for immune repertoire studies. Longer reads can improve CDR3 coverage and reduce the need for paired-end overlap assembly, a practical benefit where users seek more complete receptor information without adding complex reconstruction steps. Platform vendors retain a strong position because installed instruments influence later reagent and workflow selections. This installed base supports continuing demand in the immune repertoire sequencing market, because laboratories can adopt updated kits and longer-read options while retaining familiar operational processes, staff skills, and established vendor support structures.

Library preparation technologies are forecast to grow at a 10.22% CAGR through 2031. Growth in the immune repertoire sequencing market reflects multiplexed primer panels that profile 7 T-cell receptor and B-cell receptor chains from 1 sample. UMI-based error correction improves detection of rare clonotypes, while FFPE-compatible kits allow retrospective analysis of archived biopsies. Bioinformatics and data analysis technologies have a smaller current base but gain relevance as cloud-hosted and AI-enabled analysis expands. QIAGEN introduced QIAseq xHYB Long Read Panels in July 2025 for HLA typing, structural variants, and immune profiling with PacBio's Vega benchtop sequencer. Long-read methods can resolve full V(D)J sequences and IgH constant-region isoforms without the same level of computational reconstruction required by short-read workflows.

Complete Report Scope:

• By Product
  • Instruments
  • Assay Kits & Reagents
  • Services
  • Software
• By Technology
  • Sequencing Technologies
  • Library Preparation Technologies
  • Others
• By Receptor Type
  • T-Cell Receptor Sequencing
  • B-Cell Receptor Sequencing
• By Application
  • Oncology & Cancer Immunotherapy
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases & Vaccine Development
  • Transplantation & Immune Tolerance
  • Others
• By End-user
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Clinical Diagnostic Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.47% of the immune repertoire sequencing market share in 2025. The region has the highest concentration of FDA-cleared immune repertoire diagnostic products, large pharmaceutical research programs, and extensive academic medical center capacity. The United States has a clinical reimbursement structure for immune repertoire tests, with clonoSEQ set at USD 2,007 per test in 2025 and an episode price of USD 8,029 across covered indications. Canada contributes through academic consortium-based immune monitoring. Mexico has an earlier-stage base centered on academic imports of international assay kits, which leaves adoption more closely tied to research budgets and access to suppliers than to established clinical reimbursement. These conditions keep North America at the center of the immune repertoire sequencing market.

Europe is the second-largest regional segment. Germany, the United Kingdom, and France lead adoption through academic consortia, including EuroClonality and EuroMRD, that support quality frameworks for NGS-based clonality testing. Clinical laboratories across the region are gradually applying these frameworks, which support more consistent NGS-based clonality testing while leaving individual laboratories to meet local clinical and administrative requirements. EU IVDR 2017/746 can delay laboratory-developed test deployments because it requires more formal compliance. The same requirements can strengthen the position of vendors that achieve certified in vitro diagnostic status, because those vendors can offer laboratories a clearer path through compliance expectations. The European market combines a strong research foundation with a more demanding route to clinical commercialization. For the immune repertoire sequencing market, this creates demand for suppliers that can support evidence generation and documented quality processes.

Asia-Pacific is forecast to grow at a 13.24% CAGR through 2031, the fastest regional rate. China's National Genomics Data Center and provincial precision medicine programs support high-volume sequencing infrastructure, while BGI includes immune repertoire sequencing in its multiomics service portfolio. IMMUQUAD introduced 7-chain concurrent TCR and BCR sequencing using 5'RACE Ultra construction, which supports full-length receptor profiling from 1 sample. Japan and South Korea add demand through academic genomics programs, government-backed precision oncology infrastructure, and research activity that supports adoption of advanced immune profiling methods. India is emerging as a cost-competitive service location for international clinical-trial sample processing. The Middle East, Africa, and South America remain early adoption regions, where Saudi Arabia, the UAE, South Africa, Brazil, and Argentina provide initial demand centers. Saudi Arabia and the UAE are investing in genomics under health transformation programs, while South Africa benefits from infectious disease surveillance networks. Brazil’s Fiocruz institutes and academic networks in Argentina are important sources of demand. High import duties on sequencing instruments and limited domestic reagent production continue to constrain wider uptake, despite government-funded research pilots and distributor expansion.

List of Companies Covered in this Report:

• 10x Genomics, Inc.
• Adaptive Biotechnologies
• Agilent Technologies
• BGI
• CD Genomics
• Celemics, Inc.
• Cellecta, Inc.
• Cerba Research
• Creative Biolabs
• Danaher
• Enpicom
• Roche
• iGeneTech Bioscience Co., Ltd.
• Illumina
• iRepertoire, Inc.
• MedGenome
• New England Biolabs
• Nucleus Biotech
• Oxford Nanopore Technologies plc
• Pacific Bioscience
• Parse Biosciences
• Personalis, Inc.
• QIAGEN
• Takara Bio
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support